Author

J. W. Tyner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 4 Organism:human· 4 Research Focus:gene regulatory network inference· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:clustering· 2 Assay:DNA methylation· 2

Frequent Co-Authors

B. J. Druker· 2 shared E. Demir· 2 shared A. Koren· 1 shared B. Chang· 1 shared B. Druker· 1 shared B. Gurun· 1 shared B. M. Smith· 1 shared C. Hammond· 1 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. J. Druker

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML

V. Mohanty, N. Baran, Y. Huang, C. L. Ramage, L. M. Cooper, S. He, R. Iqbal, M. Daher, CTD2 Research Network, J. W. Tyner, G. B. Mills, M. Konopleva, K. Chen

This study identifies four transcriptionally distinct venetoclax-resistant clusters in AML, revealing phenotypic, genetic, and drug response differences and their implications for treatment resistance.

bioRxiv · Jan 27, 2024 · PreprintCancer Biology

Computational modeling of methylation impact of AML drivers reveals new pathways and refines AML risk-stratification

B. Gurun, J. W. Tyner, E. Demir, B. J. Druker, P. T. Spellman

This paper uses supervised and unsupervised models to identify new methylation pathways and improve AML risk-stratification by analyzing epigenetic changes in progenitor cells.

bioRxiv · May 17, 2023 · PreprintCancer Biology

Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia

W. M. Yashar, B. M. Smith, D. J. Coleman, J. VanCampen, G. Kong, J. Macaraeg, J. Estabrook, E. Demir, N. Long, D. Bottomly, S. K. McWeeney, J. W. Tyner, B. J. Druker, J. E. Maxson, T. P. Braun

This study shows that combining FLT3 and LSD1 inhibitors synergistically kills FLT3-mutant AML cells by disrupting the MYC super-enhancer complex.

bioRxiv · Jan 17, 2022 · PreprintCancer Biology

Replication timing alterations in leukemia reflect stable clinically-relevant changes in genome architecture

J. C. Rivera-Mulia, T. Sasaki, C. Trevilla-Garcia, N. Nakamichi, D. J. H. F. Knapp, C. Hammond, B. Chang, J. W. Tyner, M. Devidas, J. Zimmerman, K. Klein, V. Somasundaram, B. Druker, T. Gruber, A. Koren, , D. M. Gilbert

The paper compares DNA replication timing profiles of BCP-ALL leukemic samples with normal B-lineage differentiation stages to identify clinically relevant features.

bioRxiv · Apr 11, 2019 · PreprintCancer Biology